May 2, 2025
In areas where Plasmodium falciparum and Plasmodium vivax coexist, patients recovering from P. falciparum malaria remain at risk of P. vivax recurrence. The PRIMA study evaluates high-dose primaquine as a universal radical cure to prevent these recurrences. However, identifying who requires treatment remains a challenge. This presentation explores the potential of serological exposure markers (SEMs) to refine the PRIMA study by classifying P. vivax recurrence risk, enabling a more targeted approach to malaria treatment and elimination strategies.